3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
15
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral HER2 Positive Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Interventions
Trastuzumab
1
Paclitaxel
1
Epirubicin
1
Cyclophosphamide
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unilateral HER2 Positive Breast Cancer
×
Afatinib
×
Breast
×
Clear all
NCT01594177
2014-03-13
DAFNE
GBG Forschungs GmbH
Phase 2
Completed
65 enrolled